These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8279756)
41. The impact of current use of hormone replacement therapy on prognostic factors and surgical treatment of new breast cancers. Stolier AJ; Mera R; Schapira D Oncol Rep; 1998; 5(1):61-4. PubMed ID: 9458294 [TBL] [Abstract][Full Text] [Related]
42. Biochemical parameters for prognostic evaluation in patients with breast cancer. Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728 [TBL] [Abstract][Full Text] [Related]
43. Chinese female breast cancer patients show a better overall survival than their male counterparts. Xia LP; Zhou FF; Guo GF; Wang F; Wang X; Yuan ZY; Zhang B Chin Med J (Engl); 2010 Sep; 123(17):2347-52. PubMed ID: 21034547 [TBL] [Abstract][Full Text] [Related]
44. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629 [TBL] [Abstract][Full Text] [Related]
45. Oestrogen and progesterone receptors and disease-free interval in primary breast cancer. Alanko A; Heinonen E; Scheinin TM; Tolppanen EM; Vihko R Br J Cancer; 1984 Nov; 50(5):667-72. PubMed ID: 6498064 [TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma. Takei H; Iino Y; Horiguchi J; Kanoh T; Takao Y; Oyama T; Morishita Y Anticancer Res; 1995; 15(3):1101-5. PubMed ID: 7544088 [TBL] [Abstract][Full Text] [Related]
47. Characteristics of and therapeutic options for contralateral axillary lymph node metastasis in breast cancer. Morcos B; Jaradat I; El-Ghanem M Eur J Surg Oncol; 2011 May; 37(5):418-21. PubMed ID: 21316187 [TBL] [Abstract][Full Text] [Related]
48. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494 [TBL] [Abstract][Full Text] [Related]
49. [Correlation of the biochemical and histochemical determination of hormone receptors in carcinoma of the breast with the age of the patient, stage and histologic type of the neoplasm]. Campobasso O; Concina S; Cozzani C; Ribotta M; Di Carlo F; Conti G; Racca S Pathologica; 1987; 79(1059-1060):53-9. PubMed ID: 3441412 [No Abstract] [Full Text] [Related]
50. CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Begum M; Karim S; Malik A; Khurshid R; Asif M; Salim A; Nagra SA; Zaheer A; Iqbal Z; Abuzenadah AM; Alqahtani MH; Rasool M Asian Pac J Cancer Prev; 2012; 13(10):5257-61. PubMed ID: 23244146 [TBL] [Abstract][Full Text] [Related]
51. Breast cancer in postmenopausal patients: Impact of age. Abu Rabi Z; Zoranovic T; Milovanovic J; Todorovic-Rakovic N; Nikolic-Vukosavljevic D J BUON; 2015; 20(3):723-9. PubMed ID: 26214623 [TBL] [Abstract][Full Text] [Related]
52. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue]. Schulze MH; Buchmann J Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188 [TBL] [Abstract][Full Text] [Related]
53. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Yu H; Levesque MA; Clark GM; Diamandis EP Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775 [TBL] [Abstract][Full Text] [Related]
54. Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. Peters WH; Roelofs HM; van Putten WL; Jansen JB; Klijn JG; Foekens JA Br J Cancer; 1993 Jul; 68(1):86-92. PubMed ID: 8318426 [TBL] [Abstract][Full Text] [Related]
55. [Correlation between receptor status histochemically determined and clinical course in tumors of the breast: execution and extension of the study]. Gottardi O; Franchi L; Ghislandi E Pathologica; 1987; 79(1059-1060):141-7. PubMed ID: 3441404 [No Abstract] [Full Text] [Related]
56. The presence of alveolar structures in invasive ductal NOS breast carcinoma is associated with lymph node metastasis. Zavyalova MV; Perelmuter VM; Vtorushin SV; Denisov EV; Litvyakov NV; Slonimskaya EM; Cherdyntseva NV Diagn Cytopathol; 2013 Mar; 41(3):279-82. PubMed ID: 22102485 [No Abstract] [Full Text] [Related]
57. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience. Cabuk D; Basaran G; Teomete M; Dane F; Korkmaz T; Seber S; Telli F; Yumuk PF; Turhal S Asian Pac J Cancer Prev; 2014; 15(1):117-22. PubMed ID: 24528011 [TBL] [Abstract][Full Text] [Related]
58. [Prognostic and therapeutic significance of steroid receptors in invasive breast cancer]. Wyss P; Rageth JC; Unger C; Hochuli E Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):611-6. PubMed ID: 1294437 [TBL] [Abstract][Full Text] [Related]
59. Defining a high mortality risk group among women with primary breast cancer. Nordén T; Lindgren A; Bergström R; Holmberg L Br J Cancer; 1994 Mar; 69(3):520-4. PubMed ID: 8123483 [TBL] [Abstract][Full Text] [Related]
60. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Ooka M; Sakita I; Fujiwara Y; Tamaki Y; Yamamoto H; Aihara T; Miyazaki M; Kadota M; Masuda N; Sugita Y; Iwao K; Monden M Oncol Rep; 2000; 7(3):561-6. PubMed ID: 10767368 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]